Hut 8 Gets Court Approval in Bid for Four Natural Gas Power Plants
By Robb M. Stewart
Hut 8's bid for four natural-gas power plants in Ontario has secured court approval, a step forward in the digital-currency miner's expansion efforts.
The company said Monday that it received an approval and vesting order from the Ontario Superior Court of Justice as part of the continuing creditor proceedings of Validus Power.
Hut 8, in partnership with Macquarie's equipment finance arm, was last month successful in a stalking horse bid for the power plants, including a Bitcoin mine.
With the court approval, Hut 8 will become majority owner of the assets while Macquarie will gain a roughly 20% stake in a new Hut 8 subsidiary. Completion of the deal, which is expected to close by Feb. 15, will include a secured funding arrangement with Macquarie and Hut 8's subsidiary in the form of an operating lease facility.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
January 08, 2024 07:17 ET (12:17 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track